AAREYDRUGS vs SHILPAMED: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Shilpa Medicare Limited

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Shilpa Medicare Limited is the larger company by market capitalisation. Shilpa Medicare Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Shilpa Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 1 of 13 scored metrics and SHILPAMED on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SHILPAMED is the larger company
₹12,013 Cr vs ₹221 Cr
P/E Ratio
SHILPAMED has a lower P/E
51.29x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 4.82x
EPS
SHILPAMED has higher earnings per share
₹12.44 vs ₹1.47
Dividend Yield
SHILPAMED has a higher dividend yield
0.08% vs 0%
Revenue Growth (TTM YoY)
SHILPAMED has faster revenue growth
31.5% vs 19.8%
EPS Growth (TTM YoY)
SHILPAMED has faster EPS growth
644.6% vs -41.05%
Qtr Sales Growth
SHILPAMED has stronger quarterly sales growth
32.1% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSSHILPAMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSSHILPAMED
Live Price₹90.51₹615
Day Change-4.92%-3.91%
Volume2.2 L4.9 L
52-Week High₹96₹860
52-Week Low₹50.31₹259.5
Distance from 52W High-5.72%-28.49%

Valuation

MetricAAREYDRUGSSHILPAMED
Market Cap₹221 Cr₹12,013 Cr
P/E Ratio55.36x51.29x
P/B Ratio1.46x4.82x
EPS₹1.47₹12.44
Book Value₹48.67₹132.46
Dividend Yield0%0.08%

Growth

MetricAAREYDRUGSSHILPAMED
Revenue Growth (TTM YoY)19.8%31.5%
EPS Growth (TTM YoY)-41.05%644.6%
Qtr Sales Growth0%32.1%
Qtr Profit Growth0%148%

Profitability & Leverage

MetricAAREYDRUGSSHILPAMED
ROE2.64%9.4%
ROCE6%11%
Net Margin0.84%15.82%
Operating Margin2.21%28.2%
Debt to Equity0.33x0.25x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSSHILPAMED
Promoter Holding37.71% 1.35 pp40.13%
FII Holding4.18% 0.32 pp11.38% 0.3 pp
DII Holding1.62% 1.62 pp8.05% 0.53 pp
Public Holding56.49% 0.6 pp40.43% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Shilpa Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.